Scientific investigations sometimes result in serendipitous discoveries which shift the investigations from one focus to another. In the case of researchers at Mayo Clinic in Arizona, studies addressing obesity’s impact on cancer treatment resulted in an unexpected discovery that shifted the focus from cancer to obesity. The investigators observed that two common cancer-fighting drugs sparked significant weight loss in the obese mice, even though the mice continued their excessive consumption of a high-fat diet.
These results, which are part of a Mayo Clinic study, were reported in the Jan. 17 edition of Oncotarget.
“We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only targeted their cancers, but also tended to spontaneously resolve their obesity ? even with undiminished gorging on a high-fat diet,” says Mayo Clinic cancer immunotherapist Peter Cohen, M.D., who co-led the study with postdoctoral fellow Cheryl Myers, Ph.D. and Mayo Clinic immunologist Sandra Gendler, Ph.D.
“Importantly, two chemotherapy agents ? methotrexate and cyclophosphamide ? could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer,” explains Dr. Myers. “Interestingly, these drugs are already used to treat some noncancerous conditions, such as rheumatoid arthritis.”
More research needs to be done to see if the same outcome can be achieved in morbidly obese patients.
“The ease with which this weight loss was achieved in mice ? even with continued caloric binging ? is in stark contrast to the Herculean difficulties morbidly obese patients experience trying to preserve weight loss through dietary restraint,” adds Dr. Gendler.
The weight reduction observed in the obese mice was not attributable to trivial explanations, such as a decrease in dietary intake, increased energy expenditure or malabsorption. Instead, the investigators identified multiple effects of methotrexate or cyclophosphamide that worked together to expedite loss of excessive weight in mice. Much like chemotherapy’s well-known ability to decrease red and white blood cell precursors transiently, methotrexate or cyclophosphamide depleted fat cell precursors, leading to much decreased fat storage. “This meant that excessive dietary calories had to go somewhere else in the body instead, such as to the liver,” explains Dr. Cohen.
“Surprisingly, the liver maintained a robust level of metabolic activity during methotrexate or cyclophosphamide treatment, but was nearly shut down in regards to fat production and fat storage,” adds Dr. Myers.
“Based on our composite data,” explains Dr. Gendler, “it appears that methotrexate or cyclophosphamide can induce the livers of obese mice to burn off rather than accumulate excessive dietary fat. This results in desirable weight reduction instead of increased obesity, even with continued caloric binging.”
The study sets the stage for further research, exploring how these metabolic mechanisms could reduce the need for severe dietary constraints in morbidly obese individuals.
Receive an email update when we add a new WEIGHT LOSS article.
The Latest on: Methotrexate and cyclophosphamide
via Google News
The Latest on: Methotrexate and cyclophosphamide
- HIV-related Lymphomaon October 31, 2019 at 5:00 pm
BEMOP: Bleomycin, etoposide, vincristine, methotrexate and prednisolone; CA: Cyclophosphamide and doxorubicin; CDE: Cyclophosphamide, doxorubicin and etoposide; CHOP ...
- A Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil (H-45408)on September 9, 2019 at 5:00 pm
1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus ...
- Standard Adjuvant Chemotherapy Compared to Capecitabine in Early Breast Canceron August 27, 2019 at 2:34 pm
Patients were randomized to receive capecitabine alone or a standard adjuvant chemotherapy regimen, which was the physician’s choice of cyclophosphamide, methotrexate, and fluorouracil (CMF) or ...
- A trial looking at treatment for children and young adults with an ependymoma (SIOP Ependymoma Program II) Pathway 2on August 6, 2019 at 5:00 pm
cyclophosphamide and high dose methotrexate After this a small amount of tumour might remain. Where possible you have further surgery to remove it. Where this isn’t possible giving 2 more doses of ...
- Is chemotherapy effective for rheumatoid arthritis?on June 20, 2019 at 12:11 pm
However, they may not begin to see the full benefit of methotrexate until after 12 weeks. Cyclophosphamide is a potent chemotherapy drug that can cause more severe side effects than methotrexate.
- Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Canceron June 12, 2019 at 5:00 pm
In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four ...
- How is the drug methotrexate used off-label to help treat MS?on May 29, 2019 at 5:00 pm
Partners Multiple Sclerosis Center: "Cyclophosphamide (Cytoxan)." Tisch MS Research Center of New York: "Safety of Long-term Intrathecal Methotrexate Therapy in Progressive Forms of Multiple Sclerosis ...
- Barrett Esophagus after Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF): An Iatrogenic Injury?on February 15, 2019 at 4:07 am
Requests for Reprints: Sergio Sartori, MD, II Department of Medicine and Oncology Service, St. Anna General Hospital, corso Giovecca 203, 44100 Ferrara, Italy ...
- Can chemotherapy help treat Crohn's?on December 20, 2018 at 1:06 pm
People taking methotrexate may require regular checkups ... and anyone taking the drug should report all side effects to their doctor. Cyclophosphamide (Cytoxan) is another chemotherapy drug that may ...
via Bing News